In addition, the administration of PPAR-α agonists was related to the decrease of the LPL inhibitor apolipoprotein C III in patients affected by metabolic syndrome, type 2 diabetes and dyslipidemia [108]. This evidence concerns the gene LPL and metabolic syndrome.